Li Li, Schuster Isaiah P, Jacob Robin, Hupart Kenneth H, Gotlieb Vladimir
Department of Medicine, Nassau University Medical Center, East Meadow, NY USA.
Springerplus. 2013 Oct 17;2:536. doi: 10.1186/2193-1801-2-536. eCollection 2013.
The expression of hormone receptors (HR) is considered a good prognostic marker in uterine sarcoma. Hormonal therapy is widely employed in the therapy of HR positive breast and gynecologic cancers, however, there is little information concerning hormonal therapy in HR positive extrauterine sarcoma. A 55-60 year age group female presented with an estrogen receptor positive metastatic retroperitoneal leiomyosarcoma (LMS). She was treated with four cycles of a combination of Gemcitabine and Paclitaxel. Her disease remained stable for 29 months when tamoxifen was initiated. The patient succumbed to an unrelated malignancy after a total of 44 months of treatment. Despite emerging reports about the potential benefit of hormonal therapy, selective estrogen and progesterone receptor modulators and aromatase inhibitors, for uterine sarcoma, there is a paucity of information regarding the application of these therapies to sarcomas arising at other sites. Our patient survived significantly longer than expected with metastatic retroperitoneal sarcoma. In part this may be due to the survival benefit associated with HR positive tumors, but it may also indicate a role for hormonal therapy which has yet to be explored.
激素受体（HR）的表达被认为是子宫肉瘤的一个良好预后标志物。激素疗法广泛应用于HR阳性乳腺癌和妇科癌症的治疗，然而，关于HR阳性子宫外肉瘤的激素疗法的信息却很少。一名55 - 60岁的女性患者被诊断为雌激素受体阳性的转移性腹膜后平滑肌肉瘤（LMS）。她接受了四个周期的吉西他滨和紫杉醇联合治疗。当开始使用他莫昔芬时，她的病情稳定了29个月。在总共44个月的治疗后，患者死于一种无关的恶性肿瘤。尽管有新的报道称激素疗法、选择性雌激素和孕激素受体调节剂以及芳香化酶抑制剂对子宫肉瘤可能有益，但关于这些疗法在其他部位发生的肉瘤中的应用信息却很少。我们的患者转移性腹膜后肉瘤的存活时间明显长于预期。部分原因可能是与HR阳性肿瘤相关的生存获益，但这也可能表明激素疗法的作用尚未得到探索。
